Searching for a molecule that enhances CD22-targeting rIT in vivo, we found the combination with paclitaxel to eradicate leukemia cells in 60% of KOPN-8-bearing mice which survive tumor-free for months. This evidence concerns the gene CD22 and neoplasm.